LINK Strengthens Presence in Japan with Cosmo Bio and Shigematsu Distribution Agreements
LINK has announced the appointment of two new distributors in Japan — Cosmo Bio and Shigematsu. The companies will work alongside LINK’s current partner, Gene Design, thus strengthening LINK’s presence in this important market and increasing access to its range of innovative reagents for oligo therapeutics and diagnostics.
Cosmo Bio, based in Tokyo, offer a wide range of research reagents and instruments, having been established in the Japanese life science research community for over 30 years. The company represents over 600 domestic and international manufacturers, listing over 10 million products across the entire spectrum of life science research. Mr Yoshiyuki Maki, Director of Cosmo Bio, commented: “We are proud to distribute LINK’s high quality oligonucleotide reagents in the Japanese research market. We have a keen desire to support the development of the life science market, and this new agreement allows us to expand our Advanced Technology product portfolio, further strengthening our position as a leading partner for life science researchers in Japan.”
Based in Osaka, with offices in Tokyo, Tsukuba-city and Minami-aoyama, Shigematsu & Co. have over 50 years’ experience in serving the chemical reagent market, across various fields such as pharmaceuticals, diagnostics, chemicals, foods, electronics, as well as academic and public institutions within Japan. Mr Kenshiro Shigematsu, Director, Marketing & Development at Shigematsu, said: “It gives us great pleasure, and a sense of pride, to be partnering with LINK, and we look forward to helping the company achieve increased success in Japan’s growing oligonucleotide reagent market.”
Dr David Ricketts, CEO of LINK, added: “Japan is an important market for us, but also a complex one. It is essential therefore that we reach customers by more than one channel, to increase choice and value for customers seeking to source and use our products. Adding to the excellent work of our initial partner in Japan, Gene Design, these appointments broaden our reach and underline our ambition and focus to meet customers’ needs on a global scale. We very much look forward to working with our newest partners in Japan to take our business forward.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.